Some Medicare Part D plans did not cover generic versions of pricey hepatitis C drugs in 2019, leaving millions in savings on the table, according to a new watchdog report. The report, released ...
Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa. The Big Biotech is turning to TV again to promote its hep C franchise, this ...
More than a decade before Gilead’s patents expire for blockbuster hep C drugs Epclusa and Harvoni, the company is actually launching authorized generics at one-third the list price—or less. To say ...
Generics a Commonsense Answer to High Drug Prices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results